BioSpace News Archive

Policy

Evogen’s Cognizance Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent for Its Diagnostic Biomarkers for Epilepsy

New Patent Provides Further Protection for Neuro-Inflammatory Biomarkers for the Diagnosis of Epileptic Seizures

October 10, 2018
·
4 min read
Drug Development

MaxCyte Commences Dosing in First Clinical Trial in Solid Tumors

First patient dosed in Phase I clinical study to evaluate MaxCyte’s lead CAR therapeutic in ovarian cancer and peritoneal mesothelioma

October 10, 2018
·
3 min read
Deals

Kodiak Sciences Inc. Announces Closing of Initial Public Offering

Kodiak Sciences Inc. today announced the closing on October 9, 2018 of its initial public offering of 9,000,000 shares of common stock at a price to the public of $10.00 per share.

October 10, 2018
·
1 min read
Business

Alnylam Appoints Dr. Margaret Hamburg to Board of Directors

Dr. Hamburg is Former FDA Commissioner and Internationally Recognized as a Distinguished Authority in Medicine, Regulatory Science and Public Health

October 10, 2018
·
8 min read
Drug Development

Antibe Therapeutics Receives Approval to Initiate Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Antibe Therapeutics Inc. is pleased to announce that it has received approval from Health Canada to initiate the first part of its Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346.

October 10, 2018
·
3 min read
Business

Rheos Medicines Expands Leadership Team with Appointments of Gad Soffer as Chief Operating Officer and J. Duncan Higgons to Board of Directors

Biopharmaceutical executives bring substantial global business development and operations experience to advance immunometabolism for novel medicines

October 10, 2018
·
4 min read
Business

Tris Pharma Announces Hiring of Chief Commercial Officer

Tris Pharma, Inc. today announced the appointment of Thomas Curatolo as Chief Commercial Officer to lead Tris’ expanded Attention Deficit Hyperactivity Disorder (ADHD) portfolio.

October 10, 2018
·
2 min read
FSD Pharma Congratulates High Tide Inc. for Closing Oversubscribed Private Placement and Announces $2 Million Lead Order

FSD Pharma Inc. would like to congratulate High Tide Inc. (“High Tide”) on closing the second tranche of its brokered private placement (the “Offering”), for gross proceeds of approximately $18.3 million.

October 10, 2018
·
3 min read
FDA

Neovasc Reducer™ Granted Breakthrough Device Designation from FDA

Neovasc Inc. today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Breakthrough Device designation to the Neovasc Reducer™

October 10, 2018
·
9 min read
Drug Development

New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018

Ozanimod showed effects on cognitive processing speed in a post hoc analysis of 12-month data from SUNBEAM™ pivotal trial

October 10, 2018
·
9 min read